Temporary Post Used For Theme Detection (b11d39dc-39e1-46c9-a77a-fbce35dd6f2e – 3bfe001a-32de-4114-a6b4-4005b770f6d7) 7 March 2012 / By scottmoore / Uncategorized / 0 comments
C3i at BioPharma Asia Convention 2012 24 February 2012 / By Valerie Lim / Clinical Trials / 0 comments
Elcam Medical at BioPharma Asia Convention 2012 24 February 2012 / By Valerie Lim / Uncategorized / 0 comments
George McCormick, #Teva Pharmaceuticals on the biggest challenges in #drug safety 24 February 2012 / By sarah / Drug Safety / 0 comments
AE reporting through the Yellow Card System – how well does it work? 23 February 2012 / By alice / Supply Chain & Manufacturing / 0 comments
Exhibitor spotlight: Colder Products Company 21 February 2012 / By Valerie Lim / Uncategorized / 0 comments
What does disappointing results of Gilead’s oral Hep C drug mean for early development in direct-acting antivirals? 21 February 2012 / By nicklong / Clinical Trials / 0 comments
4 Reasons why the pharma industry is facing exponential change 21 February 2012 / By rebeccal / Regulation and Government / 1 comment
